Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 469 clinical trials
featured
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC).  

merkel cell carcinoma
cancer
metastatic cancer
carcinoma
measurable disease
  • 101 views
  • 14 Dec, 2020
  • 7 locations
featured
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic

metastatic cancer
pd-l1
measurable disease
cancer
  • 91 views
  • 10 Dec, 2020
  • 23 locations
featured
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.  

solid tumors
cancer
solid tumor
metastatic cancer
measurable disease
  • 38 views
  • 14 Dec, 2020
  • 13 locations
featured
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

solid tumor
malignant solid tumor
advanced solid tumor
  • 405 views
  • 08 Jul, 2021
  • 73 locations
featured
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Characterize the safety and tolerability, and evaluate Pharmacokinetics of MRTX849 in combination with TNO155 in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecute inhibitor of KRASG12C. TNO155 is a selective, orally bioavailable allosteric inhibitor of wild type SHP2.

advanced solid tumor
solid tumors
malignant solid tumor
solid tumor
  • 114 views
  • 19 Feb, 2021
  • 10 locations
featured
[Remote] The Impact of Emotions on Social Distancing Adherence and Caregiver Self-efficacy among Caregivers for individuals with Alzheimer’s disease or related dementias during the COVID-19 Pandemic

The purpose of this research study is to understand the factors (e.g., feeling unhappy, lonely, frustrated) that influence compliance with social distancing recommendations during the COVID-19 pandemic. In addition, this study aims to understand how negative emotions (e.g., feeling unhappy, lonely, frustrated) along with social distancing requirements influence family caregivers’ …

  • 43 views
  • 29 Apr, 2021
  • 244 locations
First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors

The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone or in combination with programmed cell death protein-1 (PD-1) inhibitors in treating solid cancers. ABBV-CLS-579 is an investigational drug being developed for the treatment of solid tumors. The study has two arms - …

  • 5 views
  • 04 Jul, 2021
  • 8 locations
The Method ISET (Insulation by Size of Epithelial Tumor Cells)

The aim of this study is, i) to assess the presence and the frequency of CTC in NSCLC patients undergoing surgery by using cytopathological analysis after their isolation by size (ISET method), and, ii) to correlate the presence of CNHC with pTNM stage, histological subtype, and percentage of tumor cells …

carcinoma
  • 1 views
  • 07 Nov, 2020
  • 1 location
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent. The trial aims to establish a safe, tolerable, and efficacious dose of ABBV-CLS-484 as monotherapy and in combination. The study will be conducted in three parts. Part …

  • 0 views
  • 19 Jun, 2021
  • 5 locations
Clinical Trial Comparing Dose-intensified SBRT With Conventional Radiation Therapy for Spinal Metastases

This study will compare pain (primary end-point) and local metastatic tumor control (secondary end-point) after dose-intensified image-guided fractionated stereotactic body radiation therapy

  • 0 views
  • 22 Jan, 2021